These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39044673)

  • 1. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register.
    Alexander H; Malek R; Prieto-Merino D; Gribaleva E; Baden M; Beattie P; Brown S; Burton T; Cameron S; Coker B; Cork MJ; Hearn R; Ingram JR; Irvine AD; Johnston GA; Lambert A; Lunt M; Man I; Newell L; Ogg G; Patel P; Wan M; Warren RB; Woolf R; Yiu ZZN; Reynolds N; Ardern-Jones MR; Flohr C
    Br J Dermatol; 2024 Nov; 191(6):988-999. PubMed ID: 39044673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatments for eczema: a network meta-analysis.
    Sawangjit R; Dilokthornsakul P; Lloyd-Lavery A; Lai NM; Dellavalle R; Chaiyakunapruk N
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013206. PubMed ID: 32927498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.
    Flohr C; Rosala-Hallas A; Jones AP; Beattie P; Baron S; Browne F; Brown SJ; Gach JE; Greenblatt D; Hearn R; Hilger E; Esdaile B; Cork MJ; Howard E; Lovgren ML; August S; Ashoor F; Williamson PR; McPherson T; O'Kane D; Ravenscroft J; Shaw L; Sinha MD; Spowart C; Taams LS; Thomas BR; Wan M; Sach TH; Irvine AD;
    Br J Dermatol; 2023 Nov; 189(6):674-684. PubMed ID: 37722926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
    Edwards SJ; Karner C; Jhita T; Barton S; Marceniuk G; Yiu ZZN; Wittmann M
    Health Technol Assess; 2024 Jan; 28(4):1-113. PubMed ID: 38343072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review.
    Zheng Y; Ding RL; Bu J
    Front Immunol; 2024; 15():1367099. PubMed ID: 38812522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.
    Bosma AL; Ouwerkerk W; Heidema MJ; Prieto-Merino D; Ardern-Jones MR; Beattie P; Brown SJ; Ingram JR; Irvine AD; Ogg G; Patel P; Reynolds NJ; Hearn RMR; Wan M; Warren RB; Woolf RT; Hyseni AM; Gerbens LAA; Spuls PI; Flohr C; Middelkamp-Hup MA;
    JAAD Int; 2023 Mar; 10():14-24. PubMed ID: 36387062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
    Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
    Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
    Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
    Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network.
    Zirpel H; Ludwig RJ; Olbrich H; Kridin K; Ständer S; Thaçi D
    J Dermatolog Treat; 2024 Dec; 35(1):2421429. PubMed ID: 39489506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
    Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
    Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study.
    Hosseini-Ashrafi M; Clayton TH; Herring M; Herety N; Arkwright PD
    Clin Exp Dermatol; 2024 May; 49(6):578-583. PubMed ID: 38189448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.
    Boesjes CM; Kamphuis E; de Graaf M; Spekhorst LS; Haeck I; van der Gang LF; Loman L; Zuithoff NPA; Dekkers C; van der Rijst LP; Romeijn GLE; Oosting AJ; Gostynksi A; van Lynden-van Nes AMT; Tupker RA; van Tuyll van Serooskerken AM; Flinterman A; Politiek K; Touwslager WRH; Christoffers WA; Stewart SM; Kamsteeg M; Schuttelaar MA; de Bruin-Weller MS
    JAMA Dermatol; 2024 Oct; 160(10):1044-1055. PubMed ID: 39110432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update.
    Drucker AM; Lam M; Prieto-Merino D; Malek R; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Mohan T; Burton T; Spuls PI; Schmitt J; Flohr C
    JAMA Dermatol; 2024 Sep; 160(9):936-944. PubMed ID: 39018058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis.
    Drucker AM; Ellis AG; Bohdanowicz M; Mashayekhi S; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Küster D; Siegels D; Schmitt J; Flohr C
    JAMA Dermatol; 2020 Jun; 156(6):659-667. PubMed ID: 32320001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
    Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
    Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
    Drucker AM; Morra DE; Prieto-Merino D; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
    JAMA Dermatol; 2022 May; 158(5):523-532. PubMed ID: 35293977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients.
    Napolitano M; Ferrucci SM; Foggia L; Hansel K; Pezzolo E; Stingeni L; Antonelli E; Picone V; Patruno C
    Clin Drug Investig; 2024 Jan; 44(1):71-77. PubMed ID: 38105393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT).
    Irvine AD; Jones AP; Beattie P; Baron S; Browne F; Ashoor F; O'Neill L; Rosala-Hallas A; Sach T; Spowart C; Taams L; Walker C; Wan M; Webb N; Williamson P; Flohr C;
    Br J Dermatol; 2018 Dec; 179(6):1297-1306. PubMed ID: 29727479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.